PERSEUS trial findings suggest that modern myeloma therapies could lead to survival rates similar to age-matched controls. KLN-1010, an off-the-shelf gene therapy, demonstrated promising MRD-negative ...

Minaris will move its center for viral vector innovation to occupy space within CGT Catapult’s collaborator laboratories in London and will work with CGT Catapult on the further development of ...

Authors explore complexities in scaling gene-therapy production with special attention is to monitoring and enhancing ...

VV169 saw complete clearance of disseminated myeloma tumors within 28 daysAnother dataset highlights Vyriad’s work in improved vector retargeting strategies in a comparative study of three methods for ...

Chroma Bio ("nChroma"), a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced that it has received a ...

GERMANTOWN, MD AND CHICAGO, IL / ACCESS Newswire / December 16, 2025 / uBriGene Biosciences, a leading global lentivirus CDMO ...

An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...

ROME, Italy, Dec. 10, 2025 /PRNewswire/ -- Fondazione Telethon announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra, an ex ...

The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and older with Wiskott-Aldrich syndrome, a rare primary immunodeficiency.

Fondazione Telethon announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra, an ex vivo gene therapy for patients with Wiskott ...

Takeaway Gene corrected stem cell therapy represents a major scientific breakthrough for ADA SCID. When children are diagnosed early and treated quickly they can develop their own strong immunity and ...

The expansion of LENTIVERSEtm platform introduces "One Lentiviral Vector Platform, Two Paths to Advance Cures," aligning scientific rigor with transparent economics and global accessibility.